Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a ...

The surge in autoimmune diseases, propelled by factors such as genetic predisposition, environmental triggers, and lifestyle changes, underpins the robust growth of the diagnostics market. With ...

The steady growth trajectory of Europe’s autoimmune disease diagnostics market can be attributed to several factors. Primarily, the rising incidence of autoimmune disorders across the region ...

Despite a change in ownership, the diverse mix of tenants is expected to remain at this popular Beach Boulevard marketplace.

The blood test detects a protein biomarker to aid in the diagnosis of axial spondyloarthritis, which is often mistaken for lower back pain.

A public health advocacy group is urging the B.C. government to end its contract with the American company that owns LifeLabs ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of gains.

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.